Topical Agents for Scar Management: Are They Effective?

April 2018 | Volume 17 | Issue 4 | Original Article | 421 | Copyright © 2018

Christopher I. Zoumalan MD FACS

Keck School of Medicine, University of Southern CA; Aesthetic and Reconstructive Oculoplastic Surgery, Los Angeles, CA

Abstract

Scar formation is the body’s natural healing response to reestablish dermal integrity following an injury. Excessive scarring, however, can cause significant cosmetic, functional, and psychological problems. A wide variety of topical creams, lotions, and oils are available for scar treatment or wound healing. Sieving through the options and selecting the best option for their patients can be challenging for clinicians, especially given that clinical evidence for many of the active agents in commonly used topical treatments is lacking. The goal of this review is to provide an overview of topical treatments utilized for scar management, including their mechanism of action and evidence of efficacy. As knowledge of the wound healing process is critical to understanding the effects of topical treatments, the pathophysiology of wound healing is also reviewed.

J Drugs Dermatol. 2018;17(4):421-425.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

Scarring or scar formation is the body’s natural healing response to reestablish dermal integrity following an injury. Scars, however, are structurally different and can be functionally deficient and cosmetically less appealing than normal human skin. Pathologically, a spectrum of scars is recognized from thin almost invisible scars to stretched, depressed, and/ or contracted scars to hypertrophic and keloid scars, depending on whether or not the wound healing process was regulated correctly. Scars may also be associated with a spectrum of symptoms ranging from inflammation, erythema, dryness, and pruritus to no symptoms. Excessive scarring can cause significant cosmetic, functional, and psychological problems.1 Over the past 2 decades, research efforts have been channeled into understanding the pathophysiology of the wound healing process as well as in developing treatments for the management and prevention of scars. Consequently, a variety of treatments are currently available. While variety provides the clinician as well as the patient with choices, it also creates confusion as to how to select the most appropriate treatment for a particular type of scar.

Pathophysiology of Wound Healing

Wound healing is a complex, organized, coordinated process, which in the short-term aims to prevent infection and reestablish skin integrity and in the long-term aims to remodel and strengthen the newly formed tissue. Accordingly, wound healing may be regarded as consisting of three main stages—inflammatory, proliferative, and remodeling or maturation—that are not mutually exclusive (reviewed in Clark; Slemp et al; Eming et al; Hantash et al; Berman et al).2-6 Inflammatory PhaseThe inflammatory phase is initiated immediately following skin injury and lasts for 48 to 72 hours. It is a highly regulated process involving the nervous system, several cell types (keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets), and a network of signaling molecules (cytokines, chemokines, and growth factors) that reach the wound through vasodilation and increased blood ow to the site of injury. Clinically the inflammatory phase manifests with erythema, heat, swelling, and pain. The release of the proinflammatory cytokine interleukin-1 (IL-1) alerts surrounding cells of tissue injury and begins the reparative process. Hemorrhage from tissue damage releases blood components into the wound that activate the clotting cascade. Temporary blanching (vasoconstriction) of the wound occurs that lasts for approximately 10-15 minutes. Vasoconstriction is mediated by prostaglandins, serotonin, thromboxanes, circulating epinephrine, and norepinephrine and serves to reduce hemorrhage immediately following injury. Platelets attach and aggregate to the exposed subendothelium leading to clot formation (primary plug formation). The clot stops the bleeding, stabilizes the wound, and provides a matrix for the in ux of inflammatory cells, platelets, and plasma proteins. Platelet aggregation also activates the platelets. Activated platelets degranulate, releasing growth factors (epidermal growth factor [EGF]), platelet-derived growth factor [PDGF], and transforming growth factor-beta [TGF-β]), vasoactive agents, and proteases. Thrombin activation by the coagulation cascade results in the migration of inlammatory cells to the site of tissue injury. Mast cells produce histamine and leukotrienes, which stimulate vasodilation. Capillary vasodilation results in extravasation of serum proteins into the wound site. Polymorphonuclear (PMN) cells (neutrophils, eosinophils, and basophils) are the first inflammatory cells to arrive at the wound site. PDGF, IL-1, IL-8, and growth related oncogene play a role in attracting the PMN 

↑ back to top


Related Articles